Elite Pharmaceuticals (ELTP)
(Delayed Data from OTC)
$0.20 USD
+0.01 (2.83%)
Updated Aug 23, 2024 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Elite Pharmaceuticals Inc falls in the month of March .
All items in Millions except EPS data.
3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 | |
---|---|---|---|---|---|
Sales | 57 | 34 | 32 | 25 | 18 |
Cost Of Goods | 30 | 18 | 17 | 14 | 10 |
Gross Profit | 26 | 17 | 15 | 12 | 8 |
Selling & Adminstrative & Depr. & Amort Expenses | 16 | 13 | 10 | 10 | 10 |
Income After Depreciation & Amortization | 11 | 4 | 5 | 2 | -2 |
Non-Operating Income | -10 | 1 | 1 | 2 | 0 |
Interest Expense | 1 | 1 | 0 | 0 | 0 |
Pretax Income | 0 | 4 | 6 | 4 | -2 |
Income Taxes | -20 | 0 | -2 | -1 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 1 | 0 | 0 |
Income From Cont. Operations | 20 | 4 | 9 | 5 | -2 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 20 | 4 | 9 | 5 | -2 |
Depreciation Footnote | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 12 | 5 | 7 | 4 | -1 |
Depreciation & Amortization (Cash Flow) | 1 | 1 | 1 | 2 | 2 |
Income After Depreciation & Amortization | 11 | 4 | 5 | 2 | -2 |
Earnings Per Share Data | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Average Shares | 1,023.23 | 1,012.91 | 1,010.61 | 943.00 | 993.26 |
Diluted EPS Before Non-Recurring Items | 0.03 | 0.00 | 0.01 | 0.01 | 0.00 |
Diluted Net EPS (GAAP) | 0.02 | 0.00 | 0.01 | 0.01 | 0.00 |
Fiscal Year end for Elite Pharmaceuticals Inc falls in the month of March .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 18.80 | 17.95 | 15.54 | 14.16 | 8.98 |
Cost Of Goods | 10.33 | 9.83 | 8.50 | 7.71 | 4.23 |
Gross Profit | 8.47 | 8.12 | 7.04 | 6.45 | 4.75 |
SG&A, R&D, and Dept/Amort Expenses | 4.61 | 4.39 | 3.50 | 4.53 | 3.15 |
Income After SG&A, R&D, and Dept/Amort Expenses | 3.86 | 3.73 | 3.54 | 1.92 | 1.60 |
Non-Operating Income | -2.77 | -1.52 | -3.51 | -4.53 | -0.19 |
Interest Expense | 0.25 | 0.22 | 0.12 | 0.13 | 0.12 |
Pretax Income | 0.85 | 1.99 | -0.09 | -2.73 | 1.30 |
Income Taxes | 0.23 | -1.33 | -0.80 | -17.67 | 0.15 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 0.62 | 3.33 | 0.71 | 14.93 | 1.14 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 0.62 | 3.33 | 0.71 | 14.93 | 1.14 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 1,076.25 | 1,042.39 | 1,024.45 | 1,019.32 | 1,014.57 |
Diluted EPS Before Non-Recurring Items | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
Diluted Net EPS (GAAP) | 0.00 | 0.01 | 0.00 | 0.01 | 0.00 |